Literature DB >> 22438253

Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice.

Karl Balabanian1, Emilie Brotin, Vincent Biajoux, Laurence Bouchet-Delbos, Elodie Lainey, Odile Fenneteau, Dominique Bonnet, Laurence Fiette, Dominique Emilie, Françoise Bachelerie.   

Abstract

Desensitization controls G protein-dependent signaling of chemokine receptors. We investigate the physiologic implication of this process for CXCR4 in a mouse model harboring a heterozygous mutation of the Cxcr4 gene, which engenders a desensitization-resistant receptor. Such anomaly is linked to the warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome, a human rare combined immunodeficiency. Cxcr4(+/mutant(1013)) mice display leukocytes with enhanced responses to Cxcl12 and exhibit leukopenia as reported in patients. Treatment with CXCL12/CXCR4 antagonists transiently reverses blood anomalies, further demonstrating the causal role of the mutant receptor in the leukopenia. Strikingly, neutropenia occurs in a context of normal bone marrow architecture and granulocyte lineage maturation, indicating a minor role for Cxcr4-dependent signaling in those processes. In contrast, Cxcr4(+/1013) mice show defective thymopoiesis and B-cell development, accounting for circulating lymphopenia. Concomitantly, mature T and B cells are abnormally compartmentalized in the periphery, with a reduction of primary follicles in the spleen and their absence in lymph nodes mirrored by an unfurling of the T-cell zone. These mice provide a model to decipher the role of CXCR4 desensitization in the homeostasis of B and T cells and to investigate which manifestations of patients with WHIM syndrome may be overcome by dampening the gain of CXCR4 function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22438253     DOI: 10.1182/blood-2012-01-403378

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Chromothriptic cure of WHIM syndrome.

Authors:  David H McDermott; Ji-Liang Gao; Qian Liu; Marie Siwicki; Craig Martens; Paejonette Jacobs; Daniel Velez; Erin Yim; Christine R Bryke; Nancy Hsu; Zunyan Dai; Martha M Marquesen; Elina Stregevsky; Nana Kwatemaa; Narda Theobald; Debra A Long Priel; Stefania Pittaluga; Mark A Raffeld; Katherine R Calvo; Irina Maric; Ronan Desmond; Kevin L Holmes; Douglas B Kuhns; Karl Balabanian; Françoise Bachelerie; Stephen F Porcella; Harry L Malech; Philip M Murphy
Journal:  Cell       Date:  2015-02-05       Impact factor: 41.582

2.  Plerixafor for the Treatment of WHIM Syndrome.

Authors:  David H McDermott; Diana V Pastrana; Katherine R Calvo; Stefania Pittaluga; Daniel Velez; Elena Cho; Qian Liu; Hugh H Trout; João F Neves; Pamela J Gardner; David A Bianchi; Elizabeth A Blair; Emily M Landon; Susana L Silva; Christopher B Buck; Philip M Murphy
Journal:  N Engl J Med       Date:  2019-01-10       Impact factor: 91.245

Review 3.  Genetics on a WHIM.

Authors:  Omar Al Ustwani; Razelle Kurzrock; Meir Wetzler
Journal:  Br J Haematol       Date:  2013-09-20       Impact factor: 6.998

4.  Functional consequences of perturbed CXCL12 signal processing: analyses of immature hematopoiesis in GRK6-deficient mice.

Authors:  Doreen Chudziak; Gabriele Spohn; Darja Karpova; Katrin Dauber; Eliza Wiercinska; Johanna A Miettinen; Thalia Papayannopoulou; Halvard Bönig
Journal:  Stem Cells Dev       Date:  2014-11-19       Impact factor: 3.272

Review 5.  Cell circuits and niches controlling B cell development.

Authors:  Sandra Zehentmeier; João P Pereira
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

6.  G-protein coupled receptor (GPCR) mutations in lymphoid malignancies: linking immune signaling activation and genetic abnormalities.

Authors:  Jose Angel Martinez-Climent
Journal:  Haematologica       Date:  2018-08       Impact factor: 9.941

Review 7.  Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3.

Authors:  Philip M Murphy; Lauren Heusinkveld
Journal:  Cytokine       Date:  2018-02-15       Impact factor: 3.861

8.  The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse.

Authors:  Marinos Kallikourdis; Anna Elisa Trovato; Fabio Anselmi; Adelaida Sarukhan; Giuliana Roselli; Laura Tassone; Raffaele Badolato; Antonella Viola
Journal:  Blood       Date:  2013-06-21       Impact factor: 22.113

9.  A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.

Authors:  David H McDermott; Qian Liu; Daniel Velez; Lizbeeth Lopez; Sandra Anaya-O'Brien; Jean Ulrick; Nana Kwatemaa; Judy Starling; Thomas A Fleisher; Debra A Long Priel; Melissa A Merideth; Robert L Giuntoli; Moses O Evbuomwan; Patricia Littel; Martha M Marquesen; Dianne Hilligoss; Rosamma DeCastro; George J Grimes; Samuel T Hwang; Stefania Pittaluga; Katherine R Calvo; Pamela Stratton; Edward W Cowen; Douglas B Kuhns; Harry L Malech; Philip M Murphy
Journal:  Blood       Date:  2014-02-12       Impact factor: 22.113

10.  High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.

Authors:  Marlène Pasquet; Christine Bellanné-Chantelot; Suzanne Tavitian; Naïs Prade; Blandine Beaupain; Olivier Larochelle; Arnaud Petit; Pierre Rohrlich; Christophe Ferrand; Eric Van Den Neste; Hélène A Poirel; Thierry Lamy; Marie Ouachée-Chardin; Véronique Mansat-De Mas; Jill Corre; Christian Récher; Geneviève Plat; Françoise Bachelerie; Jean Donadieu; Eric Delabesse
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.